Brefeldin A Solution (1,000X)

Pricing & Availability
Other Names
Ave. Rating
Submit a Review
Product Citations
Cat # Size Price Quantity Avail. Save
420601 1 mL 44€
Check Availability

Need larger quantities of this item?
Request Bulk Quote

Brefeldin A (BFA) is a protein transport inhibitor commonly used to enhance intracellular cytokine staining signals by blocking transport processes during cell activation. Especially useful for the intracellular staining of cytokines, BFA leads to the accumulation of most cytokines at the Golgi Complex/Endoplasmic Reticulum (see Jung, et al., 1993). Optimal conditions for use are cell type and time-dependent. Typically, protein transport inhibitors are included during in vitro cell activation cultures for 4-24 hours prior to harvest (see references below for additional information). Brefeldin A Solution is supplied as a 1,000X solution, which should be diluted to 1X in cell culture medium.

Product Details
Technical data sheet

Product Details

Brefeldin A Solution is supplied as a 1000X in DMSO, which should be diluted to 1X in cell culture medium.
5.0 mg/ml
Storage & Handling
Store the Brefeldin A Solution (1,000X) between 2°C and 8°C. Note: DMSO freezes at this temperature.

ICFC - Quality tested

Recommended Usage

Dilute the 1000X solution to 1X in the tissue culture medium. It is recommended that cells are cultured with brefeldin A for ≤ 24 hours, as this can become toxic for cell viability.

Application Notes

Completely thaw the solution before use, DMSO freezes at 4°C.  We recommend aliquotting the reagent into smaller volumes to avoid repeated freeze-thawing.  

Application References

(PubMed link indicates BioLegend citation)
  1. O'Sullivan BJ, et al. 2006. J. Immunol. 176:7278.
  2. Fuse S, et al. 2007. J. Immunol. 178:5227.
  3. Kang YJ, et al. 2007. Nature Immunol. 8:601.
  4. Redfern CH,et al.2006.J. Clin Oncol.19:3107. PubMed
  5. Smithey MJ, et al. 2008. J. Immunol. 180:3406. PubMed
  6. Elzey BD, et al. 2008. Blood 111:38684. PubMed
  7. Nguyen KD, et al. 2008. J. Immunol. 181:5386. PubMed
  8. Miner MD, et al. 2008. Microb Pathog. 45:273. PubMed
  9. Goodridge HS, et al. 2009. J. Immunol. 182:1146. PubMed
  10. Markey KA, et al. 2009. Blood 113:5644. PubMed
  11. Wilcox RA, et al. 2009. Blood PubMed
  12. Zenaro E, et al. 2009. J. Leukoc Bio. PubMed
  13. Rozkova D, et al. 2009. Clin Immunol. 131:1. PubMed
  14. Butcher JP, et al. 2010. Clin Cancer Res. 16:2065.
  15. Boisvert M, et al. 2010. J. Virol. 84:7782. PubMed
  16. Liu WC, et al. 2010. J. Virol. 84:12011.15. Tawara I, et al. 2011. Clin Cancer Res. 17:77. PubMed
  17. Iwata Y, et al. 2011. Blood. 117:530. PubMed
  18. Schmidt NW, et al. 2011. J. Immunol. 186:3836. PubMed
  19. Langkjaer A, et al. 2012. Clin Immunol. 145:1. PubMed
  20. Molinero LL, et al. 2012. PNAS. 109:18529. PubMed
  21. Li HW, et al. 2012. J. Immunol. 189:5572. PubMed
  22. Wang JM, et al. 2013. J. Virol. 87:4372. PubMed
  23. Fukuoka A, et al. 2013. Int Immunol. 25:373. PubMed
  24. Wang Jm, et al. 2013. J Virol. 87:11626. PubMed
  25. Lee TH, et al. 2013. J Biol Chem. 288:32873. PubMed
  26. Shi L, et al. 2014. J. Immunol. 192:649. PubMed
  27. Bulati M, et al. 2014. Exp Gerontol. PubMed
  28. Blankenhaus B, et al. 2014. PLoS Pathog. 10:1003913. PubMed
  29. Tuna H, et al. 2014. J Leukoc Biol. 95:471. PubMed
  30. Miller ML, et al. 2014. PNAS. 111:7397. PubMed
  31. Wang Y, et al. 2014. Sci Rep. 4:5346. PubMed
  32. Zhou GL, et al. 2014. J Cell Sci. 127:3916. PubMed
  33. Rist MJ, et al. 2015. J Virol. 89:703. PubMed
Product Citations
  1. Rossato C, et al. 2017. Biologicals. 10.1016/j.biologicals.2017.06.007. PubMed
  2. Ruland C, et al. 2017. Brain Behav Immun. 10.1016/j.bbi.2017.06.010. PubMed
  3. Zischke J, et al. 2017. PLoS Pathogens. 13(6):e1006454. PubMed
  4. Ries M, et al. 2017. PLoS Pathog. 10.1371/journal.ppat.1006506. PubMed
  5. Martins M, et al. 2017. PLoS Pathog. 10.1371/journal.ppat.1006529. PubMed
  6. Dayoub O, et al. 2017. Sci Rep. 10.1038/s41598-017-09933-4. PubMed
  7. Orlov M, et al. 2017. PLoS One.. 10.1371/journal.pone.018296. PubMed
  8. Li L,et al. 2017. Sci Rep.. 10.1038/s41598-017-14000-z. PubMed
  9. Ahmadi H,et al. 2017. Inflammopharmacology. . 10.1007/s10787-017-0410-8. PubMed
  10. Maschmeyer P, et al. 2017. J Autoimmun.. 10.1016/j.jaut.2017.11.005. PubMed
  11. Landi A, et al. 2017. Vaccine.. 10.1016/j.vaccine.2017.10.072. PubMed
  12. Zhu S, et al. 2017. Exp Cell Res.. 10.1016/j.yexcr.2017.10.013. PubMed
  13. Orozco SL, et al. 2019. Cell Rep. 28:2275. PubMed
  14. Yuan X, et al. 2017. Elife. 6:e29540. PubMed
  15. Lu G, et al. 2017. PLoS One. 12:e0178352. PubMed
  16. Gebremeskel S, et al. 2017. Cancer Immunol Res. 0.9625. PubMed
  17. Li J, et al. 2018. Redox Biol. 0.976388889. PubMed
  18. Cao Y, et al. 2018. Nat Commun. 2.940972222. PubMed
  19. Emmer BT, et al. 2018. Elife. 7:e38839. PubMed
  20. Guo C, et al. 2018. Immunity. 49:842. PubMed
  21. Wang R, et al. 2018. Oncoimmunology. 7:e1461303. PubMed
  22. Carissimo G, et al. 2019. Life Sci Alliance. 2:e201900298. PubMed
  23. Salazar V, et al. 2019. Cell Rep. 26:1585. PubMed
  24. Ngwenyama N, et al. 2019. JCI Insight. 4:e125527. PubMed
  25. Yamamoto A, et al. 2019. J Clin Invest. 129:3640. PubMed
  26. Piper CJM, et al. 2020. Cell Reports. 29(7):1878-1892.e7.. PubMed
  27. Raju S, et al. 2020. Cell Reports. 29(9):2556-2564.e3.. PubMed
  28. Rana A, et al. 2020. Front Immunol. 11:536. PubMed
  29. Good Z, et al. 2019. Nat Biotechnol. 37:259. PubMed
  30. Gogokhia L, et al. 2019. Cell Host Microbe. 25:285. PubMed
  31. Rosser EC, et al. 2020. Cell Metabolism. 31(4):837-851. PubMed
  32. Hassan AO, et al. 2020. Cell. 183:169. PubMed
  33. Sekine T, et al. 2020. Cell. 183:158. PubMed
  34. Wang Y, et al. 2020. Sci Adv. 6:eaba5412. PubMed
  35. Kalafati L, et al. 2020. Cell. 183:771. PubMed

Antigen Details

Antigen References

1. Current Protocols in Immunology (John Wiley & Sons New York) Unit 6.24 Detection of Intracellular Cytokines by Flow Cytometry (Barbara Foster and Calman Prussin NIAID NIH Bethesda MD).
2. Sander B, et al. 1991. Immunol. Rev. 119:65.
3. Sander B, et al. 1993. J. Immunol. Meth. 166:201.
4. Prussin C, et al. 1995. J. Immunol. Meth. 188:117.
5. Jung T, et al. 1993. J. Immunol. Meth. 159:197.

Gene ID

Related FAQs

How do I choose monensin or Brefeldin A solution?

Generally, Brefeldin A is more toxic for longer term incubations, so for shorter stimulations (6 hrs or less) use Brefeldin A.  For longer stimulations use monensin.  We recommend optimization for each cell type and protocol.

The Brefeldin A solution freezes at 4°C . Is the solution still OK?

We recommend to thaw in warm water after removing from the fridge.  The Brefeldin A is dissolved in DMSO, which freezes at 18°C, so this is normal.  No one has reported any problems with the freeze/thaw cycles and this is how we recommend it is stored.   If customers are concerned, they can aliquot the Brefeldin A to avoid the freeze thaw.

Go To Top Version: 1    Revision Date: 11.30.2012

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.


*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.


BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

Insert Note Here
Save Close Clear
Lab Timer
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account